AB-201

DB18629InvestigationalCell transplant therapies

AB-201 is a CAR-NK cell therapy targeted against HER2. It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Also known as: Ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15
Code names: AB-201

Resolves to

Targets

P04626ERBB2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with AB-201, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account